CLSI NBS05-A

CLSI NBS05-A

Click here to purchase
Cystic fibrosis (CF), a common genetic disorder, is due to mutations in the Cystic Fibrosis Transmembrane ConductanceRegulator (CFTR) gene. Early diagnosis through newborn screening (NBS) benefits patients with CF and is now practicedthroughout the United States, Australasia, and most western European countries. This guideline was developed with internationalconsensus and describes comprehensively the laboratory tests for detecting CF risk among newborns as well as recommendationsfor follow-up care. The document focuses on the use of immunoreactive trypsinogen (IRT) assays and the detection of specificCFTR mutations with the IRT/deoxyribonucleic acid screening strategy. Special attention is given to CFTR mutations ingeographically and ethnically diverse populations. A core panel of CFTR mutations is recommended with guidance included on itspotential expansion. The intended target audience includes NBS laboratory and program personnel, regulatory agencies, CF centerpersonnel, neonatologists, primary care providers, organizations responsible for networks of CF centers, and a variety of publichealth policy makers.

Product Details

File Size:
1 file , 2.3 MB

You may also like

CLSI VET01S

CLSI VET01S

Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From Animals, 6th Edition, VET01SEd6Estandard by Clinical and...

CLSI EP33

CLSI EP33

Use of Delta Checks in the Medical Laboratory, 2nd Edition, EP33Ed2Estandard by Clinical and Laboratory Standards Institute, 06/01/2023

CLSI EP25-Ed2

CLSI EP25-Ed2

Evaluation of Stability of In Vitro Medical Laboratory Test Reagents, 2nd Edition, EP25Ed2Estandard by Clinical and Laboratory Standards Institute, 04/26/2023

CLSI PRE04

CLSI PRE04

Handling, Transport, Processing, and Storage of Blood Specimens for Routine Laboratory Examinations, 1st Edition, PRE04Ed1Estandard by Clinical and Laboratory Standards...

Back to Top